Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) in Invasive Cardiology
NCT ID: NCT01612117
Last Updated: 2014-05-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
244 participants
OBSERVATIONAL
2011-11-30
2012-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will be conducted to assess the possible value of urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) as an early detector of contrast-induced nephropathy (CIN) in a large sized cohort of patients undergoing percutaneous coronary procedures (PCP) and whether or not uNGAL correlates with the volume of contrast medium (CM) used.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neutrophil Gelatinase-associated Lipocalin as a New Biomarker to Detect Acute Kidney Injury in Postoperative Cardiac Surgery
NCT01594788
NGAL Predictive Value of Acute Kidney Failure After Cardiac Surgery in Patients With Preoperative Chronic Kidney Failure
NCT01227122
Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury
NCT01122225
Neutrophil Gelatinase-Associated Lipocalin: Biomarker of Acute Kidney Injury After Cardiac Surgery
NCT00594919
Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury
NCT00445809
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
consecutive, PCP patients
All patients requiring percutaneous coronary procedures, such as coronary angiography or intervention
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
* lack of written consent
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Freiburg
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stéphane Cook, Prof
Ms
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephane Cook, MD
Role: STUDY_CHAIR
University Fribourg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cardiology
Fribourg, Canton of Fribourg, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Perrin T, Descombes E, Magnin JL, Gachet M, Hemett OM, Hayoz D, Stolt V, Baeriswyl G, Stauffer JC, Goy JJ, Togni M, Cook S. Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) and contrast-induced acute kidney injury after coronary angiogram. Swiss Med Wkly. 2013 Aug 27;143:w13853. doi: 10.4414/smw.2013.13853. eCollection 2013.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
013-REP-CER-FR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.